DMAC vs MCK · $157.4M cap vs P/E 20, rev $403.43B
DiaMedica Therapeutics Inc (DMAC) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
DMAC currently screens at market cap $157.4M. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the DMAC and MCK stock pages for the full models.
Not investment advice.